Introduction
Type 2 diabetes mellitus (T2DM) is a long-term metabolic disorder that results from defects in both insulin action and insulin secretion. T2DM is associated with serious micro-and macrovascular complications affecting several organs, including the heart and blood vessels, liver, eyes, muscles, skin, brain, and kidneys, thus resulting in significant mortality and morbidity rates. The prevalence of T2DM is rising rapidly; according to a recent report the total number of people with diabetes is estimated to reach 642 million individuals by 2040 worldwide. In Turkey, diabetes seems to be a serious health problem among the population because the national raw prevalence rate of diabetes in Turkey was about 14.56% in 2013, while the mean raw rate in 23 other European populations in the same year was about 7.06% (in the age group of 20-79 years) (1, 2) .
The human calpain-10 (CAPN10) gene, which encodes 672 amino acid intracellular proteases with 15 exons, is associated with the development of T2DM (3) . The human glucocorticoid receptor (NR3C1) gene was localized to band q31-32 of chromosome 5. Excess glucocorticoid levels induce glucose intolerance, insulin resistance, and β-cell dysfunction and are associated with incident diabetes (4) .
In this study, the SNP-19 and SNP-44 polymorphisms of the CAPN10 gene and the N363S polymorphisms of the NR3C1 gene were genotyped in a Turkish population with T2DM to analyze the correlation between the genotypes and the clinicopathological features of the patients.
about the purpose of the study and a written informed consent form was signed by all participants. The study was approved by the Gazi University Faculty of Medicine's Clinical Research Ethics Committee (Acceptance Date: 15/06/2011, Acceptance Number: 228). Demographic and biochemical parameters including age, sex, weight, body mass index (BMI), duration of T2DM, glycated hemoglobin (HbA 1C ), total cholesterol (TC), postprandial blood glucose (PBG), fasting blood glucose (FBG), lowdensity lipoprotein (LDL), plasma triglyceride (TG), and high-density lipoprotein (HDL) levels were measured.
Genotyping
The genomic DNA was extracted from peripheral blood leukocytes using the salting-out method and eluted in Tris-EDTA buffer. A polymerase chain reactionrestriction length polymorphism (PCR-RFLP) method was used to genotype SNP-19 (insertion/deletion) in intron 6 and SNP-44 (T/C) in intron 3 of the CAPN10 gene and N363S (A/G) in exon 2 of the NR3C1 gene. PCR amplification was performed in a volume of 50 µL containing 50-100 ng of genomic DNA, 1X PCR buffer (Fermentas, Vilnius, Lithuania), 160 mM deoxynucleoside triphosphates (Fermentas), 2.0 mM MgCl 2 (Fermentas), 0.1 U of Taq DNA polymerase (Promega, Madison, WI, USA), and 0.4 µM of each primer for SNP-19 (forward: 5'-GTTTGGTTCTCTTCAGCGTGCAG-3' and reverse: 5'-CATGAACCCTGCAGGGTCTAAG-3'), for SNP-44 (forward: 5'-GCAGGGCGCTCACGCTTGCCG-3' and reverse: 5'-GCATGGCCCCCTCTCTGATTC-3'), and for N363S (forward: 5'-AGTACCTCTGGAGGACAGAT-3' and reverse: 5'-GTCCATTCTTAAGAAACAGG-3') polymorphisms. Amplification was performed as follows: an initial denaturation at 94 °C for 5 min was followed by 30 cycles of denaturation at 94 °C for 30 s, annealing at 64 °C for 1 min and 72 °C for 1 min, and a final elongation at 72 °C for 5 min for CAPN10 SNP-19 and SNP-44, while an initial denaturation at 96 °C for 5 min was followed by 35 cycles of denaturation at 95 °C for 30 s, annealing at 54 °C for 30 s and 72 °C for 30 s, and a final elongation at 72 °C for 7 min for NR3C1 N363S polymorphisms. After amplification, 10 µL of PCR products of SNP-19 were separated on 3% agarose gel incorporated with ethidium bromide. The CAPN10 SNP-19 was an insertion/deletion polymorphism consisting of two or three repeats of a 32-bp sequence; 146-bp and 178-bp amplification product bands were identified for del-allele (two repeats) and insallele (three repeats), respectively. PCR products (10 µL) of SNP-44 and N363S were separated on 2% agarose gel and visualized by ethidium bromide. A negative control was included in each amplification analysis. The amplified genomic DNA fragments were digested at 37 °C for 1 h with BstUI (Bsh1236I) restriction enzyme (New England Biolabs, Hitchin, UK) for genotyping of SNP-44 and with TasI (Tsp5091) restriction enzyme (New England Biolabs) for genotyping of N363S polymorphisms. The 166-bp amplicon for SNP-44 was restricted by BstUI into 145-and 21-bp fragments for the C-allele. A 249-bp amplicon for the NR3C1 N363S polymorphism with two TasI restriction sites (135 bp, 95 bp, and 19 bp) for the A-allele and only one restriction site (154 bp and 95 bp) for the G-allele was obtained. Following enzymatic digestion, PCR products were subjected to electrophoresis on 3% agarose gel and stained with ethidium bromide.
Statistical analysis
All statistical analyses were performed using the SPSS 20.0 (IBM Corp., Armonk, NY, USA). All values are expressed as mean ± standard deviation. Normally distributed variables were compared between T2DM patients and the control group using Student's t-test. The correspondence of the distribution of the genotype and allele frequencies to Hardy-Weinberg equilibrium was assessed using the chisquare (χ 2 ) test and Fisher's exact test. In all analyses, a P ≤ 0.05 was considered statistically significant.
Results
The demographic and clinical features of the patients are given in Table 1 The genotype and allele frequencies of the investigated polymorphisms in the T2DM patients and the control group are presented in Table 2 . No statistically significant difference was found between T2DM development and allele frequencies of all studied polymorphisms: SNP-19 (P = 0.099; χ 2 = 2.728), SNP-44 (P = 0.344; χ 2 = 0.896), and N363S (P = 0.352; χ 2 = 0.865). The CAPN10 gene SNP-19 del-allele and SNP-44 C-allele and the NR3C1 gene N363S G-allele were determined to be risk factors for T2DM development. The genotype frequencies in the T2DM patient group were consistent with Hardy-Weinberg equilibrium for SNP-19 (P = 0.127; χ 2 = 2.33), SNP-44 (P = 0.075; χ 2 = 3.16), and N363S (P = 0.112; χ 2 = 2.52). There were no statistically significant differences in the genotype frequencies of the CAPN10 SNP-19, CAPN10 SNP-44, and NR3C1 N363S polymorphisms between T2DM patients and the control group.
The demographic and clinical features according to the genotype distributions of all T2DM patients are shown in Table 3 , those of female T2DM patients are shown in Table  4 , and those of male T2DM patients are shown Table 5 . C-allele carriers of the SNP-44 TC genotype were found to be associated with 1.34-fold increased risk of T2DM development in the general T2DM patient group (P = 0.216); this was 3-fold in females (P = 0.527) and 5-fold in males (P = 0.258). Likewise, the G-allele carriers of the N363S AG genotype were found to be associated with 2.41-fold increased risk of T2DM development in the general T2DM patient group (P = 0.511); this was 2.5-fold in females (P = 0.431) and 2.25-fold in males (P = 0.920). In addition, T2DM patients who were homozygous for the SNP-19 ins-allele had higher BMIs (28.44 ± 3.56 kg/ m 2 ) than those heterozygous or homozygous for del-allele (27.87 ± 2.49 kg/m 2 and 28.40 ± 4.16 kg/m 2 , respectively) (P = 0.130), and those who were heterozygous for the SNP-44 C-allele had higher BMIs (30.62 ± 3.98 kg/m 2 ) than those homozygous for the C-and T-allele (27.68 ± 3.41 kg/m 2 and 28.12 ± 3.36 kg/m 2 , respectively) (P = 0.098). Similarly, those who were heterozygous for the N363S G-allele had higher BMIs (28.08 ± 3.25 kg/m 2 ) than those homozygous for the A-allele (28.01 ± 4.40 kg/m 2 ) (P = 0.933). No homozygote for the N363S rare G-allele was detected. Sixty-five of the 101 T2DM patients were found to be heterozygous for the N363S of NR3C1 (AG genotype and G-allele frequency: 0.644).
There were no statistically significant differences in HbA 1C , FBG, PBG, TG, TC, HDL, or LDL levels and all investigated genotypes of the SNP-19, SNP-44, and N363S polymorphisms in T2DM patients (P ≥ 0.05). However, a statistically significant difference was observed for the SNP-44 genotypes in male patients with T2DM. Weight (P = 0.001), BMI (P = 0.098), HbA 1C (P = 0.329), FBG (P = 0.462), and PBG (P = 0.418) levels in patients heterozygous for SNP-44 were higher than in patients homozygous for the T-allele. Statistically significant differences for SNP-44 genotypes were observed for BMI and weight in male patients with T2DM (P = 0.031 and P = 0.004, respectively).
Hyperglycemia severity determinants (duration of T2DM, treatment of diabetes, FBG and HbA 1C levels) were not significantly different in carriers of the N363S AG and AA genotypes. In addition, significantly higher BMI (P = 0.968), TC (P = 0.732), HDL (P = 0.024), and LDL (P = 0.776) levels were observed in female patients with T2DM who had the N363S AG genotype as compared to male patients with T2DM. Statistically significant differences between N363S AA and AG genotypes were observed for HDL levels in female patients with T2DM (P = 0.024).
Discussion
We have studied the effects of CAPN10 and NR3C1 gene polymorphisms on the risk of T2DM and on the levels of HbA 1C , FBG, PBG, TC, TG, HDL, and LDL in T2DM patients and a control group living in Turkey. We tested 2 polymorphisms in the CAPN10 gene, SNP-19 and SNP-44, and a polymorphism in the NR3C1 gene, N363S, for association with T2DM using a case-control design.
In our study, no significant difference was found between the T2DM patients and the control group in terms of the CAPN10 gene SNP-19 polymorphism allele and genotype frequencies. The odds ratio between delallele and T2DM development was specified as 1.388 (95% CI = 0.940-2.049). Interestingly, the odds ratio between the del-allele and the development of T2DM in the Turkish population is remarkably similar to that reported in the Scandinavian Caucasians (5), Hispanic Americans (6), the Palestinian population (7), and the Tunisian Arab population (8) . As part of our study, the examined demographic details in analysis included higher BMIs for the T2DM patients who were homozygous for the SNP-19 ins-allele than those heterozygous or homozygous for del-allele. However, it was found that TC and TG levels were significantly lower in T2DM patients who were homozygous for the SNP-19 ins-allele. Our findings are consistent with the results reported in the Tunisian Arab population (8) . A significant association between the CAPN10 gene SNP-44 TC genotype and T2DM was found in Mexican Americans (3), the British/Irish population (9) , and the Palestinian population (7). Indeed, the results of our study suggest that the CAPN10 gene SNP-44 TC genotype is associated with increased risk of T2DM in the Turkish population.
The CAPN10 gene SNP-44 C-allele has been reported to increase T2DM development approximately 1.5-to 2.5-fold in the British population (9) and 2.7-fold in the Palestinian population (7) . Similarly, it was determined that the CAPN10 SNP-44 genotype was associated with 1.34-fold increased risk of developing T2DM in the Turkish population, with 3-fold increase in females and 5-fold in males. In addition, the SNP-44 TC genotype was associated with increased BMI in T2DM patients. This conclusion supports the results of a previous study from Turkey, which reported that the CAPN10 gene SNP-44 TC genotype was associated with T2DM in a Turkish population (10) . We have also found that there is a statistically significant difference between BMI and weight with SNP-44 genotypes, especially in male Turkish T2DM patients. Taken together, the CAPN10 gene SNP-44 TC genotype in Turkish T2DM patients may be a risk factor for obesity development, especially in males.
To our knowledge, the current study is the first to examine the distribution and frequency of NR3C1 gene polymorphism and obesity has been demonstrated, initially reported with a higher BMI in G-allele carriers than in A-allele carriers in elderly Dutch individuals (4) . In contrast to studies reporting that N363S polymorphism is associated with obesity in nondiabetic individuals, we found that NR3C1 gene N363S polymorphism was also associated with obesity in Turkish patients with T2DM. We observed that the N363S G-allele in Turkish T2DM patients was associated with increased weight, BMI, and HDL levels compared to the A-allele. This result of our study is consistent with the results of a study that found many atherosclerotic risk factors in AngloCeltic obesity patients without diabetes and hypertension, especially increased TC and TG concentrations, and high TC/HDL ratios are associated with N363S polymorphism (11) . Likewise, in the present study, we found that HDL was positively associated with N363S polymorphism of the NR3C1 gene, especially in Turkish female T2DM patients. Therefore, the relationship between N363S variation and HDL levels should be explored in greater detail.
A correlation was demonstrated between CAPN10 gene SNP-19 and SNP-44 and NR3C1 N363S polymorphisms and T2DM development. The CAPN10 and NR3C1 genes are fundamentally important in future research on genetic profiles. Further studies have to be supported to determine SNP molecular effects with more examples of analyzed linkage for possible effects of T2DM pathogenicity. Further studies are required with increased numbers of samples in a wider population.
